The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial ...

Fintel reports that on March 18, 2025, RBC Capital initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Clearside Biomedical (NASDAQ:CLSD – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

(RTTNews) - Innovent Biologics Inc. and HUTCHMED (China) Limited announced that the FRUSICA-2 Phase 2/3 clinical trial, which evaluated sintilimab in combination with fruquintinib as second-line ...

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

prostate cancer therapy Xtandi (enzalutamide), and Inlyta (axitinib) for kidney cancer. That shift could protect the company from some of the price-cutting measures in the Inflation Reduction Act ...